Shots:

• The P-IIb dose-finding induction study evaluates izencitinib (PO- qd) vs PBO in 239 patients with a mod. to sev. active UC for 8wks. The results from the P-II study for CD is expected in late Q4’21 or early Q1’22
• The study did not meet 1EPs & 2EPs of change in total Mayo score & clinical remission @8wks. Additionally- the therapy showed an improvement in clinical response measured by adapted Mayo score with a reduction in rectal bleeding & was well-tolerated
• The P-IIb results will support induction & maintenance dose regimens for the P-III studies. Additionally- the results from the P-II study for CD is expected in Q4’21 or Q1’22

Click here  | Ref: Theravance Biopharma | Image: PR Newswire